Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod in GERD with Incomplete PPI Response
NCT00171418Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Tegaserod + PPI with Placebo + PPI (2 arms). Primary endpoint: Clinically meaningful incremental gain in improvement of overall GERD symptoms at 4 weeks. Started Jun 2003; status: completed.
02
Drugs
tegaserod
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00171418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171418.